Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher’s AI Network Medicine ...
Buy thesis: undervalued despite 700% surge, $193M cash runway to 2029, epilepsy & schizophrenia pipeline catalysts. See more ...
Farage resigns as MP to trigger Clacton by-election amid investigations. Farage winning the by-election at 94.6% YES.
Combined company plans to advance nebokitug, a first-in-class anti-CCL24 antibody, through a precision medicine Phase 2 trial in rheumatoid arthritis (RA) by leveraging Scipher's AI Network Medicine ...
Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...
Silevertinib, Black Diamond Therapeutics' lead asset, showed strong Phase 2 results with 60% ORR and 86% CNS ORR. Read why ...
SpaceX (NASDAQ:SPCX) begins trading as a Nasdaq 100 constituent today, less than a month after going public, and Wall Street ...
Through predictive modelling, AI supports target identification, prediction of physicochemical properties and formulation strategy selection.
Even having to play "catch-up", the new Auburn head coach is beating out some of the best head coaches on the recruiting ...
Suze Orman has spent years telling her audience that the standard retirement withdrawal advice could leave them broke. “The ...
By 2028, 27,000 new commercial companies with a combined turnover of £10.8bn are expected to emerge from UK universitiesSome ...
Short sellers piled into SpaceX (NASDAQ:SPCX) faster than almost any newly public stock in recent memory, and the position is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results